The Difference in Prognostic Outcomes Between De Novo Stage IV and Recurrent Metastatic Patients with Hormone Receptor-positive, HER2-negative Breast Cancer

Conclusion: De novo patients had better prognoses than recurrent patients with DFI<2 years or AFI<1 year, likely due to their therapy-naïve status or lower resistance to systemic treatment.

Source: In Vivo - February 23, 2018 Category: Research Authors: YAMAMURA, J., KAMIGAKI, S., FUJITA, J., OSATO, H., KOMOIKE, Y. Tags: Clinical Studies Source Type: research